MAPT and Alzheimer disease: Preclinical study of the non-radioactive compound [19F]-S16 demonstrated excellent fluorescent properties and high selectivity for NFTs in brain sections from tau transgenic mice and AD patients, which indicated that it might be a promising positron emission tomography (PET) tracer for tau imaging (Zhou et al., 2021).